Analyst Research Report Snapshot

Title:

GENMAB - CUTTING A DASH AT ASH

Price:

$10.00

Provider:

Edison Investment Research

Date:

15 Nov 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

GEN.CO

Available for Immediate Download
Summary:

Expanding Arzerra’s label should help drive uptake of Genmab/GSK’s approved antibody. Detailed data from the positive front-line CLL trial will be presented at ASH and should support approval in this indication. US approval could be granted during H114 given its breakthrough designation. Daratumumab continues to progress, with first data from the ongoing Len Dex combination multiple myeloma trial available at ASH.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.